Management of Side Effects of Androgen Deprivation Therapy

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 655-671

  Grossmann, Mathis ^a,b   Zajac, Jeffrey D ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Androgen deprivation; Insulin resistance; Osteoporosis; Prostate cancer; Testosterone

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTIDIABETIC AGENT; CALCIUM; CYPROTERONE ACETATE; DENOSUMAB; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PAMIDRONIC ACID; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

AEROBIC EXERCISE; ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FRACTURE; GLUCOSE METABOLISM; GYNECOMASTIA; HAIR LOSS; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERINSULINEMIA; HYPOGONADISM; INSULIN RESISTANCE; LIFE EXPECTANCY; LIFESTYLE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD; MORTALITY; MUSCLE ATROPHY; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RESISTANCE TRAINING; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL; VASOMOTOR DISORDER; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DIETARY SUPPLEMENTS; DRUG TOXICITY; HUMANS; LIFE STYLE; MALE; PROSTATIC NEOPLASMS;

EID: 80052190917     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.004     Document Type: Review

References (97)

1. Crawford E.D. Epidemiology of prostate cancer. Urology 2003, 62:3-12.
2. SEER. Surveillance, Epidemiology and End Results (SEER): stat fact sheets: prostate cancer 2008. Available at: Accessed August 26, 2010. http://seercancergov/statfacts/html/prosthtml.
3. Satariano W.A., Ragland K.E., Van Den Eeden S.K. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998, 83:1180-1188.
4. Lu-Yao G., Stukel T.A., Yao S.L. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004, 171:2285-2290.
5. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
6. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294:238-244.
7. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 1984, 311:1281-1286.
8. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
9. Shahani S., Braga-Basaria M., Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008, 93:2042-2049.
10. Grossmann M., Hamilton E.J., Gilfillan C., et al. Bone and metabolic health in patients with prostate cancer receiving androgen deprivation therapy-management guidelines on behalf of the Endocrine Society of Australia, the Australian and New Zealand Bone and Mineral Society, and the Urological Society of Australia and New Zealand. Med J Aust 2011, 194:301-306.
11. Wong Y.N., Freedland S.J., Egleston B., et al. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol 2009, 56:609-616.
12. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation versus radiation alone for prostate cancer: a randomized trial. JAMA 2008, 299:289-295.
13. Network NCC. NCCN practice guidelines in oncology. Version 1. Available at: Accessed August 1, 2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
14. Smith M.R. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007, 14:247-254.
15. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010, 95:3-10.
16. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010, 33:562-568.
17. Tangen C.M., Faulkner J.R., Crawford E.D., et al. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2003, 2:41-45.
18. Smith D.P., King M.T., Egger S., et al. Quality of life 3 years after diagnosis of localised prostate cancer: population based cohort study. BMJ 2009, 339:b4817.
19. Lubeck D.P., Grossfeld G.D., Carroll P.R. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001, 58:94-100.
20. Nelson C.J., Lee J.S., Gamboa M.C., et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008, 113:1097-1106.
21. Salminen E., Portin R., Korpela J., et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 2003, 89:971-976.
22. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of the " androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006, 166:465-471.
23. Handelsman D.J., Zajac J.D. 11: androgen deficiency and replacement therapy in men. Med J Aust 2004, 180:529-535.
24. Strum S.B., McDermed J.E., Scholz M.C., et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997, 79:933-941.
25. Hyde Z., Flicker L., Almeida O.P., et al. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab 2010, 95:3165-3172.
26. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
27. MacLean H.E., Chiu W.S., Notini A.J., et al. Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J 2008, 22:2676-2689.
28. Haseen F., Murray L.J., Cardwell C.R., et al. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 2010, 4:128-139.
29. Basaria S., Lieb J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56:779-786.
30. Galvao D.A., Taaffe D.R., Spry N., et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010, 28:340-347.
31. Segal R.J., Reid R.D., Courneya K.S., et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003, 21:1653-1659.
32. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study. J Clin Oncol 2001, 19:3750-3757.
33. Teloken P.E., Ohebshalom M., Mohideen N., et al. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 2007, 178:2521-2525.
34. Irani J., Salomon L., Oba R., et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010, 11:147-154.
35. Loprinzi C.L., Michalak J.C., Quella S.K., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994, 331:347-352.
36. Quella S.K., Loprinzi C.L., Sloan J., et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999, 162:98-102.
37. Loprinzi C.L., Barton D.L., Carpenter L.A., et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 2004, 79:1247-1251.
38. Boccardo F., Rubagotti A., Battaglia M., et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005, 23:808-815.
39. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
40. Holmes-Walker D.J., Woo H., Gurney H., et al. Maintaining bone health in patients with prostate cancer. Med J Aust 2006, 184:176-179.
41. Greenspan S.L. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 2008, 93:2-7.
42. Higano C.S. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?. Nat Clin Pract Urol 2008, 5:24-34.
43. Greenspan S.L., Coates P., Sereika S.M., et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005, 90:6410-6417.
44. Diamond T.H., Higano C.S., Smith M.R., et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100:892-899.
45. Morote J., Orsola A., Abascal J.M., et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006, 175:1679-1683. [discussion: 1683].
46. Morote J., Morin J.P., Orsola A., et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 2007, 69:500-504.
47. Hamilton E.J., Ghasem-Zadeh A., Gianatti E., et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 2010, 95(12):E456-E463.
48. MacLean H.E., Moore A.J., Sastra S.A., et al. DNA-binding-dependent androgen receptor signaling contributes to gender differences and has physiological actions in males and females. J Endocrinol 2010, 206:93-103.
49. Chiang C., Chiu M., Moore A.J., et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res 2009, 24:621-631.
50. Smith M.R., Lee W.C., Brandman J., et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005, 23:7897-7903.
51. Smith M.R., Boyce S.P., Moyneur E., et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006, 175:136-139. [discussion: 139].
52. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
53. Abrahamsen B., Nielsen M.F., Eskildsen P., et al. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007, 100:749-754.
54. Oefelein M.G., Ricchuiti V., Conrad W., et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001, 166:1724-1728.
55. Alibhai S.M., Duong-Hua M., Cheung A.M., et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 2010, 184:918-924.
56. Taylor L.G., Canfield S.E., Du X.L. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009, 115:2388-2399.
57. Panju A.H., Breunis H., Cheung A.M., et al. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 2009, 103:753-757.
58. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 2005, 103:237-241.
59. Ebeling P.R. Clinical practice. Osteoporosis in men. N Engl J Med 2008, 358:1474-1482.
60. Galvao D.A., Nosaka K., Taaffe D.R., et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exercise 2006, 38:2045-2052.
61. Giovannucci E., Rimm E.B., Wolk A., et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998, 58:442-447.
62. Diamond T.H., Bucci J., Kersley J.H., et al. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol 2004, 172:529-532.
63. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948-955.
64. Diamond T.H., Winters J., Smith A., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001, 92:1444-1450.
65. Michaelson M.D., Kaufman D.S., Lee H., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
66. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
67. Satoh T., Kimura M., Matsumoto K., et al. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 2009, 115:3468-3474.
68. Ryan C.W., Huo D., Bylow K., et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007, 100:70-75.
69. Greenspan S.L., Nelson J.B., Trump D.L., et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416-424.
70. Planas J., Trilla E., Raventos C., et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 2009, 104(11):1637-1640.
71. Ishizaka K., Machida T., Kobayashi S., et al. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007, 14:1071-1075.
72. Izumi K., Mizokami A., Sugimoto K., et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009, 73:1342-1346.
73. Smith M.R., Egerdie B., Hernandez Toriz N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
74. Smith M.R., Morton R.A., Barnette K.G., et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010, 184(4):1316-1321.
75. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008, 179:152-155.
76. Reid D.M., Doughty J., Eastell R., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008, 34(Suppl 1):S3-S18.
77. Ito K., Elkin E.B., Girotra M., et al. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010, 152:621-629.
78. Grossmann M., Thomas M.C., Panagiotopoulos S., et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008, 93:1834-1840.
79. Allan C.A., McLachlan R.I. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol (Oxf) 2004, 60:653-670.
80. Grossmann M., Gianatti E.J., Zajac J.D. Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010, 17:247-256.
81. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599-603.
82. Smith M.R., Lee H., Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-1308.
83. Shepherd P.R., Kahn B.B. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med 1999, 341:248-257.
84. Gilsanz V., Chalfant J., Mo A.O., et al. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab 2009, 94:3387-3393.
85. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86:4261-4267.
86. Dockery F., Bulpitt C.J., Agarwal S., et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003, 104:195-201.
87. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
88. Alibhai S.M., Duong-Hua M., Sutradhar R., et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009, 27:3452-3458.
89. Eri L.M., Urdal P., Bechensteen A.G. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995, 154:100-104.
90. Despres J.P., Lamarche B., Mauriege P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
91. Faris J.E., Smith M.R. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 2010, 17:240-246.
92. Saigal C.S., Gore J.L., Krupski T.L., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110:1493-1500.
93. Van Hemelrick M., Garmo H., Bratt H., et al. Increased cardiovascular morbidity and mortality following endocrine treatment for prostate cancer: an analysis in 30,642 men in PCBaSe Sweden. Eur J Cancer Suppl 2009, 7:1.
94. Keating N.L., O'Malley A.J., Freedland S.J., et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010, 102:39-46.
95. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25:2420-2425.
96. Levine G.N., D'Amico A.V., Berger P., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010, 121:833-840.
97. Twigg S.M., Kamp M.C., Davis T.M., et al. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007, 186:461-465.